The oral solution offers precise dosing, benefiting patients with swallowing difficulties or requiring tailored dosing.

Imkeldi is supplied as a strawberry-flavored oral solution in a 140 mL, child-resistant, tamper-evident bottle.

Imkeldi is a new formulation of imatinib approved as a strawberry-flavored, shelf-stable liquid designed to be more appealing ...

Imkeldi is supplied as a strawberry-flavored oral solution in a 140mL child resistant tamper-evident bottle. The Food and Drug Administration (FDA) has approved Imkeldi, an oral solution ...

In 2001, a Time Magazine cover story touted Novartis’ targeted leukemia treatment Gleevec (imatinib) as a new kind of “ammunition in the war against cancer.” Along with a picture of the ...

Imatinib oral solution has gained FDA approval for the treatment of some cancers, including certain forms of leukemia.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the FDA has approved IMKELDI (imatinib) oral solution, the ...

FDA has approved imatinib (IMKELDI), the first oral liquid tyrosine kinase inhibitor for treating leukemia and a range of cancers, including CML, GIST, and Ph+ ALL. Developed by Shorla Oncology ...